[Skip to Content]
[Skip to Content Landing]
Views 257
Citations 0
Biotech Innovations
July 11, 2017

Spark Advances Gene Therapy for Inherited Vision Loss

JAMA. 2017;318(2):116. doi:10.1001/jama.2017.8767

Spark Therapeutics is poised to bring the first gene therapy for an inherited disorder to market in the United States. In May, the company completed its rolling biologics license application submission to the US Food and Drug Administration (FDA) for voretigene neparvovec, a gene therapy for RPE65-mediated inherited retinal disease, a rare retinal dystrophy that causes blindness.

First Page Preview View Large
First page PDF preview
First page PDF preview
×